J. B. Chemicals & Pharmaceuticals Limited Stock

Equities

JBCHEPHARM

INE572A01036

Pharmaceuticals

Delayed Bombay S.E. 01:02:10 2024-05-27 am EDT 5-day change 1st Jan Change
1,744 INR +4.56% Intraday chart for J. B. Chemicals & Pharmaceuticals Limited -1.68% +7.57%
Sales 2024 34.84B 419M Sales 2025 * 40.56B 488M Capitalization 259B 3.12B
Net income 2024 5.53B 66.49M Net income 2025 * 7.02B 84.51M EV / Sales 2024 7.35 x
Net Debt 2024 * 1.32B 15.87M Net cash position 2025 * 5.26B 63.25M EV / Sales 2025 * 6.25 x
P/E ratio 2024
47.3 x
P/E ratio 2025 *
37.1 x
Employees 5,095
Yield 2024 *
0.67%
Yield 2025 *
0.95%
Free-Float 45.82%
More Fundamentals * Assessed data
Dynamic Chart
Jefferies Adjusts JB Chemicals & Pharmaceuticals' Price Target to INR2,060 From INR2,000, Keeps at Buy MT
Transcript : J. B. Chemicals & Pharmaceuticals Limited, Q4 2024 Earnings Call, May 21, 2024
J. B. Chemicals & Pharmaceuticals Limited Recommends Final Dividend for the Year 2023-2024 CI
J. B. Chemicals & Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 CI
J. B. Chemicals & Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI
KKR to buy India's Healthium Medtech at $839 million valuation, sources say RE
J. B. Chemicals & Pharmaceuticals Limited Receives Order from Joint Commissioner State Tax, Lucknow II, Lucknow CI
J. B. Chemicals & Pharmaceuticals Limited Appoints Akshay Tanna as A Non-Executive, Non-Independent Director CI
J. B. Chemicals & Pharmaceuticals Limited Receives Order from Assessment Unit, Income Tax Department CI
J. B. Chemicals & Pharmaceuticals Limited Announces Demise of Ranjit Shahani, Chairman and Non-Executive, Independent Director CI
KKR Reportedly Considers Selling Controlling Stake in JB Pharma CI
Jefferies Adjusts JB Chemicals & Pharmaceuticals' Price Target to INR2,000 From INR1,970, Keeps at Buy MT
JB Chemicals' Consolidated Profit Climbs in Fiscal Q3; Shares Jump 4% MT
J.B. Pharma Seeks Acquisitions CI
Transcript : J. B. Chemicals & Pharmaceuticals Limited, Q3 2024 Earnings Call, Feb 07, 2024
More news

Latest transcript on J. B. Chemicals & Pharmaceuticals Limited

1 day+4.73%
1 week-1.68%
Current month-8.23%
1 month-8.34%
3 months+6.27%
6 months+25.68%
Current year+7.57%
More quotes
1 week
1 646.80
Extreme 1646.8
1 862.85
1 month
1 646.80
Extreme 1646.8
1 919.10
Current year
1 473.95
Extreme 1473.95
1 935.00
1 year
1 025.03
Extreme 1025.025
1 935.00
3 years
669.53
Extreme 669.525
1 935.00
5 years
160.85
Extreme 160.85
1 935.00
10 years
68.38
Extreme 68.375
1 935.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 20-10-04
Chief Operating Officer - -
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 59 20-08-30
Director/Board Member 40 Nov. 06
Director/Board Member 48 21-02-09
More insiders
Date Price Change Volume
24-05-27 1,744 +4.56% 8 156
24-05-24 1,668 -0.61% 5,050
24-05-23 1,679 -1.35% 5,100
24-05-22 1,702 -4.24% 8,625
24-05-21 1,777 -3.45% 3,253

Delayed Quote Bombay S.E., May 27, 2024 at 01:02 am EDT

More quotes
J. B. Chemicals & Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is engaged in the business of manufacturing and marketing of diverse range of pharmaceutical formulations, herbal remedies and active pharmaceutical ingredients (APIs). Its therapeutic categories include gastroenterology, hypertension, diabetes, dermatology, nephrology, wound care, anti-infectives and pharmacovigilance. The Company's lozenges products include center-filled, soft-centered lozenges; center-filled, powder lozenges; herbal lozenges, and medicated lozenges. The Company offers a complete range of contrast media products including X-ray, MRI, and ultrasound in India as well as internationally. The Company produces a wide range of dosage forms, such as tablets, capsules, liquids, IV infusions, ampoules, vials, ointments, cold rubs, lozenges and sips. Its brands include Rantac OD, RD, Ranraft, Metrogyl ER, Metrogyl O, Nicardia XL, Sporlac EVA and Sporlac G, among others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
1,668 INR
Average target price
1,911 INR
Spread / Average Target
+14.51%
Consensus
  1. Stock Market
  2. Equities
  3. JBCHEPHARM Stock